pteridines has been researched along with Adenocarcinoma, Basal Cell in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas." | 9.16 | A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. ( Aulitzky, WE; Dittrich, C; Fleischer, F; Hollerbach, S; Merger, M; Mross, K; Munzert, G; Scheulen, ME; Schmid, RM; Schutte, J; Strumberg, D, 2012) |
| "To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells." | 7.80 | Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. ( Abastabar, M; Akbari, A; Amanpour, S; Dehpour, AR; Faghihloo, E; Ghaffari, SH; Ghahremani, MH; Heidari, M; Karimi, A; Khoshzaban, A; Mobini, GR; Muhammadnejad, S; Shidfar, F, 2014) |
| "Transforming growth factor beta (TGFbeta) is a pleiotropic factor that regulates cell proliferation, angiogenesis, metastasis, and immune suppression." | 5.34 | Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. ( Chakravarty, S; Damm, DL; Gaspar, NJ; Henson, M; Higgins, LS; Kapoun, AM; Li, G; Li, L; Medicherla, S; Muiru, GT; Murphy, A; O'Young, G; Quon, D; Reddy, M; Wong, DH, 2007) |
| "BI 2536, a novel Polo-like kinase 1 inhibitor, was assessed in patients with unresectable advanced exocrine adenocarcinoma of the pancreas." | 5.16 | A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. ( Aulitzky, WE; Dittrich, C; Fleischer, F; Hollerbach, S; Merger, M; Mross, K; Munzert, G; Scheulen, ME; Schmid, RM; Schutte, J; Strumberg, D, 2012) |
| "To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells." | 3.80 | Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma. ( Abastabar, M; Akbari, A; Amanpour, S; Dehpour, AR; Faghihloo, E; Ghaffari, SH; Ghahremani, MH; Heidari, M; Karimi, A; Khoshzaban, A; Mobini, GR; Muhammadnejad, S; Shidfar, F, 2014) |
| " Grade 4 neutropenia occurred in 37% of patients; common nonhematologic adverse events were fatigue (31%) and nausea (27%)." | 2.75 | The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. ( Frickhofen, N; Fritsch, H; Gaschler-Markefski, B; Hanft, G; Kortsik, C; Munzert, G; Reck, M; Schuler, M; Sebastian, M; von Pawel, J; Waller, CF, 2010) |
| "Transforming growth factor beta (TGFbeta) is a pleiotropic factor that regulates cell proliferation, angiogenesis, metastasis, and immune suppression." | 1.34 | Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness. ( Chakravarty, S; Damm, DL; Gaspar, NJ; Henson, M; Higgins, LS; Kapoun, AM; Li, G; Li, L; Medicherla, S; Muiru, GT; Murphy, A; O'Young, G; Quon, D; Reddy, M; Wong, DH, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akbari, A | 1 |
| Amanpour, S | 1 |
| Muhammadnejad, S | 1 |
| Ghahremani, MH | 1 |
| Ghaffari, SH | 1 |
| Dehpour, AR | 1 |
| Mobini, GR | 1 |
| Shidfar, F | 1 |
| Abastabar, M | 1 |
| Khoshzaban, A | 1 |
| Faghihloo, E | 1 |
| Karimi, A | 1 |
| Heidari, M | 1 |
| Abdulrahman, N | 1 |
| Jaballah, M | 1 |
| Poomakkoth, N | 1 |
| Riaz, S | 1 |
| Abdelaziz, S | 1 |
| Issa, A | 1 |
| Mraiche, F | 1 |
| Sebastian, M | 1 |
| Reck, M | 1 |
| Waller, CF | 1 |
| Kortsik, C | 1 |
| Frickhofen, N | 1 |
| Schuler, M | 1 |
| Fritsch, H | 1 |
| Gaschler-Markefski, B | 1 |
| Hanft, G | 1 |
| Munzert, G | 2 |
| von Pawel, J | 1 |
| Mross, K | 1 |
| Dittrich, C | 1 |
| Aulitzky, WE | 1 |
| Strumberg, D | 1 |
| Schutte, J | 1 |
| Schmid, RM | 1 |
| Hollerbach, S | 1 |
| Merger, M | 1 |
| Fleischer, F | 1 |
| Scheulen, ME | 1 |
| Ruan, JW | 1 |
| Huang, JF | 1 |
| Fu, LW | 1 |
| Huang, ZS | 1 |
| Ma, L | 1 |
| Gu, LQ | 1 |
| Gaspar, NJ | 1 |
| Li, L | 1 |
| Kapoun, AM | 1 |
| Medicherla, S | 1 |
| Reddy, M | 1 |
| Li, G | 1 |
| O'Young, G | 1 |
| Quon, D | 1 |
| Henson, M | 1 |
| Damm, DL | 1 |
| Muiru, GT | 1 |
| Murphy, A | 1 |
| Higgins, LS | 1 |
| Chakravarty, S | 1 |
| Wong, DH | 1 |
| Weiss, G | 1 |
| Glaser, K | 1 |
| Kronberger, P | 1 |
| Ambach, E | 1 |
| Fuchs, D | 1 |
| Bodner, E | 1 |
| Wachter, H | 2 |
| Reibnegger, GJ | 1 |
| Bichler, AH | 1 |
| Dapunt, O | 1 |
| Fuchs, DN | 1 |
| Fuith, LC | 1 |
| Hausen, A | 1 |
| Hetzel, HM | 1 |
| Lutz, H | 1 |
| Werner, ER | 1 |
| Jonak, JP | 1 |
| Zakrzewski, SF | 1 |
| Mead, LH | 1 |
| Allshouse, LD | 1 |
2 trials available for pteridines and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; | 2010 |
A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network.
Topics: Adenocarcinoma; Aged; Cell Cycle Proteins; Cohort Studies; Confidence Intervals; Disease-Free Surviv | 2012 |
7 other studies available for pteridines and Adenocarcinoma, Basal Cell
| Article | Year |
|---|---|
Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neopla | 2014 |
Inhibition of p90 ribosomal S6 kinase attenuates cell migration and proliferation of the human lung adenocarcinoma through phospho-GSK-3β and osteopontin.
Topics: Adenocarcinoma; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glycogen | 2016 |
[Synthesis and antitumour activities of some pteridine derivatives].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Humans; KB Cells; Lung Neoplasms; Molecular | 2004 |
Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Topics: Activin Receptors, Type I; Adenocarcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Genes, myc | 2007 |
Distinct distributions of D-erythro-neopterin in arteries and veins and its recovery by an enterohepatic circulation.
Topics: Adenocarcinoma; Adult; Aged; Arteries; Bile; Biopterins; Duodenal Ulcer; Enterohepatic Circulation; | 1992 |
Neopterin as a prognostic indicator in patients with carcinoma of the uterine cervix.
Topics: Adenocarcinoma; Adult; Biopterins; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Immu | 1986 |
Synthesis and biological activity of 2,4-diamino-6- and -7-(1-adamantyl)pteridines.
Topics: Adenocarcinoma; Amines; Animals; Bridged-Ring Compounds; Cells, Cultured; Chromatography, Thin Layer | 1972 |